Insider Sale: Horizon Therapeutics Public Limited (NASDAQ:HZNP) TEU Sells 762 Shares
Horizon Therapeutics Public Limited (NASDAQ: HZNP – Get a rating) EVP Andy Pasternak sold 762 shares of the company in a transaction dated Friday, June 10. The stock was sold at an average price of $85.36, for a total transaction of $65,044.32. Following the completion of the sale, the executive vice president now directly owns 38,897 shares of the company, valued at $3,320,247.92. The transaction was disclosed in an SEC filing, which is available via the SEC website.
Shares of NASDAQ:HZNP traded at $3.82 during midday trading on Monday, hitting $81.60. 1,351,468 shares of the company have been traded, compared to its average volume of 1,846,253. The company has a leverage ratio of 0.53, a quick ratio of 3.30 and a current ratio of 3.57 . Horizon Therapeutics Public Limited has a one-year low of $81.20 and a one-year high of $120.54. The company has a market capitalization of $18.76 billion, a price/earnings ratio of 23.40, a P/E/G ratio of 1.20 and a beta of 1.13. The stock has a 50-day moving average of $98.10 and a 200-day moving average of $99.06.
Horizon Therapeutics Public (NASDAQ:HZNP – Get a rating) last reported results on Wednesday, May 4. The biopharmaceutical company reported earnings per share (EPS) of $1.34 for the quarter, beating the consensus estimate of $1.15 by $0.19. The company posted revenue of $885.25 million for the quarter, versus $866.39 million expected by analysts. Horizon Therapeutics Public posted a net margin of 22.87% and a return on equity of 32.08%. The company’s revenue for the quarter increased by 158.5% compared to the same quarter last year. In the same quarter of the previous year, the company achieved EPS of $0.03. Sell-side analysts expect Horizon Therapeutics Public Limited to post an EPS of 5.6 for the current financial year.
Hedge funds have recently changed their stock holdings. Morgan Stanley increased its position in Horizon Therapeutics Public by 11.2% in the second quarter. Morgan Stanley now owns 753,642 shares of the biopharmaceutical company worth $70,572,000 after purchasing an additional 76,061 shares during the period. HighTower Advisors LLC increased its holdings of Horizon Therapeutics Public shares by 7.9% in the third quarter. HighTower Advisors LLC now owns 38,764 shares of the biopharmaceutical company worth $4,247,000 after acquiring 2,834 additional shares during the period. GSA Capital Partners LLP acquired a new stake in Horizon Therapeutics Public during the third quarter at a value of $247,000. Dynamic Technology Lab Private Ltd bought a new position in Horizon Therapeutics Public in the third quarter, valued at around $321,000. Finally, Guggenheim Capital LLC increased its position in Horizon Therapeutics Public by 15.9% in the third quarter. Guggenheim Capital LLC now owns 101,694 shares of the biopharmaceutical company worth $11,140,000 after purchasing an additional 13,981 shares in the last quarter. Institutional investors hold 88.39% of the company’s shares.
A number of brokerages have weighed in on HZNP. StockNews.com assumed coverage of Horizon Therapeutics Public stocks in a Thursday, March 31, report. They issued a “hold” rating on the stock. Wells Fargo & Company restated a “buy” rating and posted a price target of $133.00 on shares of Horizon Therapeutics Public in a research note on Friday, April 8. SVB Leerink began coverage of Horizon Therapeutics Public in a research note on Monday, May 23. They set a “market performance” rating and a price target of $95.00 for the company. Morgan Stanley raised its price target on Horizon Therapeutics Public from $135.00 to $140.00 and gave the stock an “overweight” rating in a Wednesday, March 2 research note. Finally, Oppenheimer began covering Horizon Therapeutics Public in a research report on Monday, March 14. They issued an “outperform” rating and a price target of $140.00 for the company. Two investment analysts gave the stock a hold rating and seven gave the company a buy rating. According to data from MarketBeat.com, the stock currently has a consensus buy rating and a consensus price target of $132.67.
About Horizon Therapeutics Public (Get a rating)
Horizon Therapeutics Public Limited Company, a biotechnology company, is focused on the discovery, development and commercialization of drugs that address the critical needs of people affected by rare, autoimmune and serious inflammatory diseases. The Company operates in two segments, Orphan and Inflammation.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Horizon Therapeutics Public right now?
Before you consider Horizon Therapeutics Public, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Horizon Therapeutics Public was not on the list.
Although Horizon Therapeutics Public currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here